MiMedx Group, Inc. (NASDAQ:MDXG) Receives $12.00 Consensus Target Price from Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been given a consensus recommendation of “Buy” by the five analysts that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.00.

Separately, StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Isthmus Partners LLC boosted its stake in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares during the last quarter. Blue Trust Inc. acquired a new position in MiMedx Group during the third quarter valued at approximately $30,000. Point72 Asset Management L.P. acquired a new position in MiMedx Group during the second quarter valued at approximately $40,000. Point72 DIFC Ltd grew its stake in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of MiMedx Group during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Price Performance

MDXG opened at $9.19 on Wednesday. MiMedx Group has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a fifty day simple moving average of $8.73 and a 200 day simple moving average of $7.26. The stock has a market cap of $1.35 billion, a P/E ratio of 16.71 and a beta of 1.98. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.